REGENERON PHARMACEUTICALS, INC. (REGN) Shares outstanding analysis
- Shares outstanding · latest quarter: Value 103.02M; Formula and calculation Own reported common class count; original count date 2026-03-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 1 year ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-03-31. Comparisons require matching class and complete dated split coverage..
- Shares outstanding · 5 years ago: Value (m); Formula and calculation Own reported common class count; original count date 2026-03-31. Comparisons require matching class and complete dated split coverage..
- Shares change · vs previous quarter: Value (m); Formula and calculation Own reported common class count; original count date 2026-03-31. Comparisons require matching class and complete dated split coverage..
Shares outstanding analysis
Overview →Financial period ending 2026-03-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Shares outstanding · latest quarter | 103.02M | Own reported common class count; original count date 2026-03-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 1 year ago | (m) | Own reported common class count; original count date 2026-03-31. Comparisons require matching class and complete dated split coverage. |
| Shares outstanding · 5 years ago | (m) | Own reported common class count; original count date 2026-03-31. Comparisons require matching class and complete dated split coverage. |
| Shares change · vs previous quarter | (m) | Own reported common class count; original count date 2026-03-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
| Shares count change · vs previous quarter | (m) | Own reported common class count; original count date 2026-03-31. Comparisons require matching class and complete dated split coverage. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current quarter shares | 103.02M shares | |
| Previous quarter shares | (m) |
Shares means common shares outstanding, adjusted to the same split basis for comparison. It is a count, not USD or convertible securities; B means billion shares.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current quarter shares (shares) | Shares count change · vs previous quarter | Shares change (%) · vs previous quarter |
|---|---|---|---|
| 2026-03-31 | 103.02M | (m) | (m) |
| 2025-12-31 | 103.90M | (m) | (m) |
| 2025-06-30 | 104.17M | (m) | (m) |
| 2025-03-31 | 106.15M | (m) | (m) |
| 2024-12-31 | 107.51M | (m) | (m) |
| 2024-09-30 | 108.07M | (m) | (m) |
| 2024-06-30 | 108.42M | (m) | (m) |
| 2024-03-31 | 108.37M | (m) | (m) |
| 2023-12-31 | 107.94M | (m) | (m) |
| 2023-09-30 | 107.13M | (m) | (m) |
| 2023-06-30 | 106.74M | (m) | (m) |
| 2023-03-31 | 107.89M | (m) | (m) |
| 2022-12-31 | 107.51M | (m) | (m) |
| 2022-09-30 | 107.08M | (m) | (m) |
| 2022-06-30 | 107.19M | (m) | (m) |
| 2022-03-31 | 108.03M | (m) | (m) |
| 2021-12-31 | 106.72M | (m) | (m) |
| 2021-09-30 | 105.72M | (m) | (m) |
| 2021-06-30 | 105.11M | (m) | (m) |
| 2021-03-31 | 104.69M | (m) | (m) |
| 2020-12-31 | 105.28M | (m) | (m) |
| 2020-09-30 | 104.86M | (m) | (m) |
| 2020-06-30 | 104.54M | (m) | (m) |
| 2020-03-31 | 110.67M | (m) | (m) |
| 2019-12-31 | 108.17M | (m) | (m) |
| 2019-09-30 | 107.95M | (m) | (m) |
| 2019-06-30 | 107.98M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |